Effect of pre-procedural interrupted apixaban on heparin anticoagulation during catheter ablation for atrial fibrillation: a prospective observational study

Journal of Interventional Cardiac Electrophysiology

Volumn 44, Issue 2, 2015, Pages 91-96

  Bin Abdulhak, Aref A ^a   Kennedy, Kevin F ^b   Gupta, Sanjaya ^b,c   Giocondo, Michael ^b,c   Ramza, Brian ^b,c   Wimmer, Alan P ^b,c  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulation; Apixaban; Atrial fibrillation; Catheter ablation; Warfarin

Indexed keywords

APIXABAN; HEPARIN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; ARTICLE; ATRIAL FIBRILLATION; BLOOD CLOTTING TIME; CATHETER ABLATION; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HUMAN; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOEMBOLISM; ADVERSE EFFECTS; COMBINATION DRUG THERAPY; COMPLICATION; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LONGITUDINAL STUDY; PEROPERATIVE CARE; PREMEDICATION; PREOPERATIVE CARE; PROCEDURES; TREATMENT OUTCOME;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FACTOR XA INHIBITORS; FEMALE; HEPARIN; HUMANS; INJECTIONS, INTRAVENOUS; INTRAOPERATIVE CARE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREMEDICATION; PREOPERATIVE CARE; PROSPECTIVE STUDIES; PYRAZOLES; PYRIDONES; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84942984938     PISSN: 1383875X     EISSN: 15728595     Source Type: Journal    
DOI: 10.1007/s10840-015-0048-7     Document Type: Article

References (18)

1. Oral, H., Chugh, A., Ozaydin, M., Good, E., Fortino, J., et al. (2006). Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation, 114, 759–765.
2. Kwak, J., Pak, H., Jang, J., Kim, S., Park, J., Choi, J., et al. (2010). Safety and convenience of continuous warfarin strategy during the periprocedural period in patients who underwent catheter ablation of atrial fibrillation. Journal of Cardiovascular Electrophysiology, 21, 620–625.
3. Bruce, C., Friedman, P., Narayan, O., Munger, T., Hammill, S., Packer, D., et al. (2008). Early heparinization decreases the incidence of left atrial thrombi detected by intracardiac echocardiography during radiofrequency ablation for atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2(3), 211–219.
4. Di Biase, L., Burkhardt, J., Mohanty, P., Sanchez, J., Horton, R., Gallinghouse, G., et al. (2010). Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation, 121(23), 2550–2556.
5. Gopinath, D., Lewis, W. R., Biase, L. D., & Natale, A. (2011). Pulmonary vein antrum isolation for atrial fibrillation on therapeutic coumadin: special considerations. Journal of Cardiovascular Electrophysiology, 22(2), 236–239.
6. Hussein, A., Martin, D., Saliba, W., Patel, D., Karim, S., Batal, O., et al. (2009). Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm, 10, 1425–1429.
7. Di Biase, L., Burkhardt, J. D., Santangeli, P., Mohanty, P., Sanchez, J. E., & Horton, R. (2014). Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of Coumadin In Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing CatheterAblation (COMPARE) randomized trial. Circulation, 129, 2638–2644.
8. Sattari, M., & Lowenthal, D. (2011). Novel oral anticoagulants in development: dabigatran, rivaroxaban, and apixaban. American Journal of Therapeutics, 18, 332–338.
9. Konduru, S., Cheema, A., Jones, P., Li, Y., Ramza, B., & Wimmer, A. (2012). Heparinization during catheter ablation for atrial fibrillation: a comparison of patients treated with dabigatran vs patients maintained on warfarin. Journal of Interventional Cardiac Electrophysiology, 35(3), 277–284.
10. Snipelisky, D., Ray, J. C., Ung, R., Duart, M., Kauffman, C., & Kusumoto, F. (2014). A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation. Journal of Interventional Cardiac Electrophysiology, 41, 231–236.
11. Granger, C., Alexander, J., & McMurray, J. (2011). Apixaban versus warfarin patients with atrial fibrillation. New England Journal of Medicine, 365, 981–992.
12. D’Agostino, R., Jr. (1998). Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statistics in Medicine, 17(19), 2265–2281.
13. Nagao, T., Inden, Y., Shimano, M., Fujita, M., Yanagisawa, S., Kato, H., et al. (2015). Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation. Pacing and Clinical Electrophysiology, 38(2), 155–163.
14. Di Biase, L., Lakkireddy, D., Trivedi, C., Deneke, T., Martinek, M., Mohanty, S., et al. (2015). Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study. Heart Rhythm, 12(6), 1162–1168.
15. Kaess, B. M., Ammar, S., Reents, T., Dillier, R., Lennerz, C., Semmler, V., et al. (2015). Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon. American Journal of Cardiology, 115, 47–51.
16. Gabus, V., Rollin, A., Maury, P., Forclaz, A., Pascale, P., Dhutia, H. et al. (2015) Short-term heparin kinetics during catheter ablation of atrial fibrillation. PACE 0: 1–9.
17. Di Biase, L., Gaita, F., Toso, E., Mohanty, P., Rutledge, N., & Yan, X. (2014). Does periprocedural anticoagulation management of atrial fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in patients undergoing radiofrequency atrial fibrillation ablation with open irrigated catheters? Results from a prospective multicenter study. Heart Rhythm, 11(5), 791–798.
18. Nagao, T., Inden, Y., Yanagisawa, S., Kato, H., Ishikawa, S., Okumura,S.,et al. (2015). Differences in activated clotting time among uninterrupted anticoagulants during the periprocedural period of atrial fibrillation ablation. Heart Rhythm.